Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin (Q33598839)

28 July 2017

1 reference

title

Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin (English)

1 reference

28 July 2017

1 reference

McConnell SA

1

1 reference

28 July 2017

Amsden GW

series ordinal

2

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

19

1 reference

28 July 2017

issue

4

1 reference

28 July 2017

page(s)

404-415

1 reference

The 'borderline methicillin-susceptible' Staphylococcus aureus

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

The E test for antimicrobial susceptibility testing of Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

The pharmacokinetics of clarithromycin and its 14-OH metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Challenges to antibiotic activity in tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Comparative pharmacokinetics of dirithromycin and erythromycin in normal volunteers with special regard to accumulation in polymorphonuclear leukocytes and in saliva

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

In vitro activity of dirithromycin (LY 237216) compared with activities of other macrolide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

In-vitro activity of dirithromycin against Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Drug interactions with intravenous and local anaesthetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

The mechanism of cyclosporine toxicity induced by clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Effect of clarithromycin on the pharmacokinetics of 2',3'-dideoxyinosine in patients who are seropositive for human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clarithromycin-associated digoxin toxicity in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Macrolide antibacterials. Drug interactions of clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

A potentially hazardous interaction between erythromycin and midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Midazolam and erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Unconsciousness associated with midazolam and erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Interactions of pre-operative erythromycin administration with general anaesthesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Drug interactions in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

A comparative study of dirithromycin and erythromycin in bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

In-vitro activity of azithromycin on Chlamydia trachomatis infected, polarized human endometrial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of out-patients with acute bacterial exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Comparative study of clarithromycin and roxithromycin in the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Safety profile of dirithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clinical toleration and safety of azithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Drug intolerance to high-dose clarithromycin among elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Adverse effects of macrolide antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Cytotoxicity of macrolide antibiotics in a cultured human liver cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

The human hepatic cytochromes P450 involved in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Effects of erythromycin on hepatic drug-metabolizing enzymes in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Substrate- and antibiotic-binding sites at the peptidyl-transferase centre of Escherichia coli ribosomes. Studies on the chloramphenicol. lincomycin and erythromycin sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Pharmacokinetics of dirithromycin in patients with impaired hepatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Penetration of macrolides into human polymorphonuclear leucocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

In vitro and in vivo antibacterial activities of clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

In-vitro activity of dirithromycin in comparison with other new and established macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

In vitro activities of oral antimicrobial agents against penicillin-resistant Streptococcus pneumoniae: implications for outpatient treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

In-vitro activities of 14-, 15- and 16-membered macrolides against gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clarithromycin-carbamazepine interaction: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Concurrent clarithromycin and cyclosporin A treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Kidney graft dysfunction after drug interaction between clarithromycin and cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clarithromycin-induced digoxin toxicity in a patient with AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clarithromycin-related toxic effects of digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Digoxin-inactivating bacteria: identification in human gut flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Life-threatening interaction between clarithromycin and disopyramide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Lovastatin and rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Pharmacokinetic interactions between erythromycin, clarithromycin, roxithromycin and phenytoin in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Erythromycin and valproate interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Erythromycin-warfarin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clinical efficacy of dirithromycin versus miocamycin in the treatment of acute bronchitis or acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clinical efficacy of dirithromycin in acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clinical efficacy of dirithromycin in pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clarithromycin versus cefaclor for the treatment of mild-to-moderate acute bacterial bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Efficacy of amoxycillin/clavulanic acid in experimental Staphylococcus aureus endocarditis in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Efficacy of clarithromycin against Mycoplasma pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Overview of the safety profile of clarithromycin suspension in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Clinical efficacy of dirithromycin versus miocamycin in tonsillopharyngitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Antibiotics: potential hazards to male fertility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

The Influence of Dirithromycin on the Pharmacokinetics of Cyclosporine in Healthy Subjects and in Renal Transplant Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Dirithromycin increases ethinyl estradiol clearance without allowing ovulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

Changes in the steady-state pharmacokinetics of theophylline during treatment with dirithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.6.404.31054

10.1592/PHCO.19.6.404.31054

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference